Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® technology platform, today announced that on February 15, 2021, the Company granted a new employee an option to purchase a total of 65,000 shares of the Company’s common stock at an exercise price per share equal to $8.64, which was the closing trading price on February 16, 2021, the date of the grant.
The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally-active antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
VP, Investor Relations & Corp. Communications
Direct: (650) 273-4999
Investor and Media Contact:
Stern Investor Relations